{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T12:17:45Z","timestamp":1790511465315,"version":"4.1.0"},"reference-count":21,"publisher":"S. Karger AG","issue":"3","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dermatology"],"published-print":{"date-parts":[[2022]]},"abstract":"<jats:p>&lt;b&gt;&lt;i&gt;Background:&lt;\/i&gt;&lt;\/b&gt; Gemcitabine is an effective single-agent chemotherapy used in advanced stages of cutaneous T-cell lymphoma (CTCL). However, gemcitabine used in the current standard regimen is frequently associated with adverse events (AE), such as an increased risk for myelosuppression and severe infections. &lt;b&gt;&lt;i&gt;Objectives:&lt;\/i&gt;&lt;\/b&gt; We investigated in this retrospective study the effect of low-dose gemcitabine in pretreated advanced-stage CTCL and in blastic plasmacytoid dendritic cell neoplasia (BPDCN) regarding overall response (OR), progression-free survival (PFS), and AE. &lt;b&gt;&lt;i&gt;Material and Methods:&lt;\/i&gt;&lt;\/b&gt; A retrospective, multicenter study was conducted on 64 CTCL and BPDCN patients treated with gemcitabine in average absolute dosage of 1,800 mg\/m&lt;sup&gt;2&lt;\/sup&gt; per cycle, which is 50% lower compared to standard dosage of 3,600 mg\/m&lt;sup&gt;2&lt;\/sup&gt; per cycle (1,200 mg\/m&lt;sup&gt;2&lt;\/sup&gt; day 1, 8, 15). Evaluation of response to therapy and AE was done 4\u20136 weeks after the sixth cycle. &lt;b&gt;&lt;i&gt;Results:&lt;\/i&gt;&lt;\/b&gt; OR was 62% with 11% demonstrating a complete response. The median time of PFS was 12 months and median time to next treatment was 7 months. Only 3\/63 patients showed serious side effects, e.g., port infection or acute renal failure. Almost 73% of the patients experienced minor to moderate side effects (CTCAE grade 0\u20132). Fatigue (27.2%), fever (22.7%), and mild blood count alteration (18.2%) were the most common AE. &lt;b&gt;&lt;i&gt;Conclusions:&lt;\/i&gt;&lt;\/b&gt; This retrospective analysis supports the use of low-dose gemcitabine therapy in CTCL, demonstrating with 62% OR and PFS of 12 months an almost identical response rate and survival as compared to the standard dose therapy reported in previous studies but with a significantly improved safety profile and tolerability.<\/jats:p>","DOI":"10.1159\/000517830","type":"journal-article","created":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T17:00:34Z","timestamp":1630602034000},"page":"498-506","source":"Crossref","is-referenced-by-count":12,"title":["Clinical Outcomes of Advanced-Stage Cutaneous Lymphoma under Low-Dose Gemcitabine Treatment: Real-Life Data from the German Cutaneous Lymphoma Network"],"prefix":"10.1159","volume":"238","author":[{"given":"Christoph","family":"Blazejak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rene","family":"Stranzenbach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janika","family":"Gosman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thilo","family":"Gambichler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarja","family":"Stendel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claus-Detlev","family":"Klemke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanna","family":"Olk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Weyermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudolf","family":"Stadler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalid","family":"Assaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"127","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.139.7.857"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/j.det.2019.05.007"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1016\/j.clml.2012.06.010"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1001\/jamadermatol.2013.5526"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-12-611830"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2017.02.027"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM198912283212603"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.2009.09230.x"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.21449"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-11-881268"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082311"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2003.04226.x"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.3816\/clm.2004.n.009"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(18)30039-5"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1023\/a:1008409601731"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.3816\/CLM.2006.n.039"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.27990"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.08.006"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.jid.2020.06.034"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1038\/sj.bjc.6605727"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e3181ae280f"}],"container-title":["Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/517830","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/517830","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,23]],"date-time":"2025-04-23T11:08:08Z","timestamp":1745406488000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000517830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":21,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2022,5,2]]},"published-print":{"date-parts":[[2022,5,10]]}},"URL":"https:\/\/doi.org\/10.1159\/000517830","archive":["Portico"],"relation":{},"ISSN":["1018-8665","1421-9832"],"issn-type":[{"value":"1018-8665","type":"print"},{"value":"1421-9832","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,9,2]]}}}